

List of Tables

Table No.	Table Caption	Page No.
1.1	Targets and available therapeutic compounds	7
5.1	Different substitutions on aryl ring of synthesized compounds(A1-B5)	43
5.2	Different substitutions on aryl ring of synthesized compounds(CP1-CP14).	44
5.3	Different substitutions on aryl ring of synthesized compounds(C1-C14).	46
5.4	Structural features of both pyrazole analogues of curcumin for QSAR model 2	50
5.5	Structural features of both pyrazole analogues of curcumin for QSAR model 2	51
6.1	Physical properties of hexahydroindazole analogues of curcumin	53
6.2	Physical properties of pyrazole analogues of curcumin	60
6.3	Physical properties of cycloheptanone analogues of curcumin	66
6.4	Antimicrobial activity of hexahydroindazole analogues of curcumin	74
6.5	Antimicrobial activity of hexahydroindazole analogues of curcumin.	77
6.6	Antimicrobial activity of synthesized cycloheptanone analogues of curcumin	79
6.7	Inhibitory concentrations (IC ₅₀) of active samples tested against <i>P. falciparum</i> clone W2 (Chloroquine-resistant).	81
6.8	Antimalarial activity classification of samples tested against <i>P. falciparum</i> clone W2 (Chloroquine-resistant)	83
6.9	Cytotoxic concentrations (CC ₅₀) of curcumin analogues that inhibits growth of 50% of HepG2 cells.	84
6.10	Comparison of anti-malarial activity and cytotoxicity on basis of selectivity index	85
6.11	Theoretical ADME prediction of hexahydroindazole analogues of curcumin using PreADMET Server.	86
6.12	Molecular docking of hexahydroindazole analogues of curcumin with glucosamine-6-phosphate synthase.	87
6.13	Theoretical ADME prediction of pyrazole analogues of curcumin using PreADMET Server.	89
6.14	Molecular docking of pyrazole analogues of curcumin with glucosamine-6-phosphate synthase at Active Site1.	90

6.15	Molecular docking of pyrazole analogues of curcumin with glucosamine-6-phosphate synthase at Active Site 2.	91
6.16	Statistics of significant equations.	95
